About Curileum Discovery Ltd
Curileum Discovery Ltd is a newly funded regenerative medicine company in London identifying the underlying causes of serious gastrointestinal (GI) diseases, and repairing or replacing damaged cells in tissues.
We are engaging pharmaceutical collaborative partnerships in IBD, cancer, and conditions with major GI complications (diabetes and ageing) to discover a whole new range of novel, validated therapeutic targets for our partners’ development pipelines.
Our hypothesis-driven approach focuses on targeting intestinal stem cells with small molecule or biologic therapeutics to correct imbalances in the number or functional properties of cells that contribute to disease pathologies: killing defective or ineffective stem cells, managing inflammation, and activating healthy stem cells, rare cells in tissues that are the very source of lifelong tissue renewal, to restore health to the intestine.
Our operations are based on the campus of St Mark's Hospital in North West London, a major tertiary care centre solely dedicated to intestinal and colorectal medicine (20k endoscopies/year). With access to a large supply of patient tissues and leading clinical collaborators, we can rapidly test hypotheses on defined patient populations to discover and support target development for therapeutics and molecular diagnostics to improve health of patients.
State of Ownership
Chief Product Officer, Zapnito
CEO & Co-Founder, Zapnito
Sales Account Executive, Springer Nature